SEARCH

SEARCH BY CITATION

References

  • 1
    Sarafianos S.G., Das K., Hughes S.H., Arnold E. (2004) Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol;14:716730.
  • 2
    De Clercq E. (2004) Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers;1:4464.
  • 3
    Basavapathruni A., Anderson K.S. (2007) Reverse transcription of the HIV-1 pandemic. FASEB J;21:37953808.
  • 4
    Sluis-Cremer N., Tachedjian G. (2008) Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res;134:147156.
  • 5
    Jochmans D. (2008) Novel HIV-1 reverse transcriptase inhibitors. Virus Res;134:171185.
  • 6
    Ilina T., Parniak M.A. (2008) Inhibitors of HIV-1 reverse transcriptase. Adv Pharmacol;56:121167.
  • 7
    Peliska J.A., Benkovic S.J. (1992) Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Science;258:11121118.
  • 8
    DeStefano J.J., Bambara R.A., Fay P.J. (1993) Parameters that influence the binding of human immunodeficiency virus reverse transcriptase to nucleic acid structures. Biochemistry;32:69086915.
  • 9
    Cirino N.M., Cameron C.E., Smith J.S., Rausch J.W., Roth M.J., Benkovic S.J., Le Grice S.F. (1995) Divalent cation modulation of the ribonuclease functions of human immunodeficiency virus reverse transcriptase. Biochemistry;34:99369943.
  • 10
    Ghosh M., Williams J., Powell M.D., Levin J.G., Le Grice S.F. (1997) Mutating a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters primer utilization. Biochemistry;36:57585768.
  • 11
    Loya S., Hizi A. (1993) The interaction of illimaquinone, a selective inhibitor of the RNase H activity, with the reverse transcriptases of human immunodeficiency and murine leukemia retroviruses. J Biol Chem;268:93239328.
  • 12
    Palaniappan C., Fay P.J., Bambara R.A. (1995) Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J Biol Chem;270:48614869.
  • 13
    Borkow G., Fletcher R.S., Barnard J., Arion D., Motakis D., Dmitrienko G.I., Parniak M.A. (1997) Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry;36:31793185.
  • 14
    Budihas S.R., Gorshkova I., Gaidamakov S., Wamiru A., Bona M.K., Parniak M.A., Crouch R.J., McMahon J.B., Beutler J.A., Le Grice S.F. (2005) Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res;33:12491256.
  • 15
    Shaw-Reid C.A., Feuston B., Munshi V., Getty K., Krueger J., Hazuda D.J., Parniak M.A., Miller M.D., Lewis D. (2005) Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry;44:15951606.
  • 16
    Tramontano E., Esposito F., Badas R., Di Santo R., Costi R., La Colla P. (2005) 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res;65:117124.
  • 17
    Schultz S.J., Champoux J.J. (2008) RNase H activity: structure, specificity, and function in reverse transcription. Virus Res;134:86103.
  • 18
    Wendeler M., Lee H.F., Bermingham A., Miller J.T., Chertov O., Bona M.K., Baichoo N.S., Ehteshami M., Beutler J., O’Keefe B.R., Götte M., Kvaratskhelia M., Le Grice S. (2008) Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. ACS Chem Biol;3:635644.
  • 19
    Sarafianos S.G., Marchand B., Das K., Himmel D.M., Parniak M.A., Hughes S.H., Arnold E. (2009) Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol;385:693713.
  • 20
    Kirschberg T.A., Balakrishnan M., Squires N.H., Barnes T., Brendza K.M., Chen X., Eisenberg E.J. et al. (2009) RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem;52:57815784.
  • 21
    Himmel D.M., Maegley K.A., Pauly T.A., Bauman J.D., Das K., Dharia C., Clark A.D.J., Ryan K., Hickey M.J., Love R.A., Hughes S.H., Bergqvist S., Arnold E. (2009) Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure;17:16251635.
  • 22
    Su H.P., Yan Y., Prasad G.S., Smith R.F., Daniels C.L., Abeywickrema P.D., Reid J.C. et al. (2010) Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol;84:76257633.
  • 23
    Yan J., Wu H., Tom T., Brodsky O., Maegley K. (2011) Targeting divalent metal ions at the active site of the HIV-1 RNase H domain: NMR studies on the interactions of divalent metal ions with RNase H and its inhibitors. Am J Anal Chem;2:639649.
  • 24
    Gong Q., Menon L., Ilina T., Miller L.G., Ahn J., Parniak M.A., Ishima R. (2011) Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor. Chem Biol Drug Des;77:3947.
  • 25
    Davies J.F.N., Hostomska Z., Hostomsky Z., Jordan S.R., Matthews D.A. (1991) Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science;252:8895.
  • 26
    Felts A.K., Labarge K., Bauman J.D., Patel D.V., Himmel D.M., Arnold E., Parniak M.A., Levy R.M. (2011) Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies. J Chem Inf Model;51:19861998.
  • 27
    Keck J.L., Marqusee S. (1995) Substitution of a highly basic helix/loop sequence into the RNase H domain of human immunodeficiency virus reverse transcriptase restores its Mn(2+)-dependent RNase H activity. Proc Natl Acad Sci U S A;92:27402744.
  • 28
    Stahl S.J., Kaufman J.D., Vikić-Topić S., Crouch R.J., Wingfield P.T. (1994) Construction of an enzymatically active ribonuclease H domain of human immunodeficiency virus type 1 reverse transcriptase. Protein Eng;7:11031108.
  • 29
    Shaw-Reid C.A., Munshi V., Graham P., Wolfe A., Witmer M., Danzeisen R., Olsen D.B., Carroll S.S., Embrey M., Wai J.S., Miller M.D., Cole J.L., Hazuda D.J. (2003) Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem;278:27772780.
  • 30
    Ahn J., Byeon I.J., Dharmasena S., Huber K., Concel J., Gronenborn A.M., Sluis-Cremer N. (2010) The RNA binding protein HuR does not interact directly with HIV-1 reverse transcriptase and does not affect reverse transcription in vitro. Retrovirology;7:40.
  • 31
    Cavanagh J., Fairbrother W.J., Palmer A.G.I., Skelton N.J. (1996) Protein NMR Spectroscopy. San Diego: Academic Press.
  • 32
    Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. (1995) Nmrpipe – a multidimensional spectral processing system based on Unix pipes. J Biomol NMR;6:277293.
  • 33
    Johnson B.A. (2004) Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol Biol;278:313352.
  • 34
    Vranken W.F., Boucher W., Stevens T.J., Fogh R.H., Pajon A., Llinás M., Ulrich E.L., Markley J.L., Ionides J., Laue E.D. (2005) The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins: Struct, Funct, Bioinf;59:687696.
  • 35
    Bahrami A., Assadi A.H., Markley J.L., Eghbalnia H.R. (2009) Probabilistic interaction network of evidence algorithm and its application to complete labeling of peak lists from protein NMR spectroscopy. PLoS Comput Biol;5:e1000307.
  • 36
    Fielding L. (2007) NMR methods for the determination of protein–ligand dissociation constants. Prog NMR Spec;51:219242.
  • 37
    Webb C., Upadhyay A., Giuntini F., Eggleston I., Furutani-Seiki M., Ishima R., Bagby S. (2011) Structural features and ligand binding properties of tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway. Biochemistry;50:33003309.
  • 38
    Himmel D.M., Sarafianos S.G., Dharmasena S., Hossain M.M., McCoy-Simandle K., Ilina T., Clark A.D.J., Knight J.L., Julias J.G., Clark P.K., Krogh-Jespersen K., Levy R.M., Hughes S.H., Parniak M.A., Arnold E. (2006) HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site. ACS Chem Biol;1:702712.
  • 39
    Pari K., Mueller G.A., DeRose E.F., Kirby T.W., London R.E. (2003) Solution structure of the RNase H domain of the HIV-1 reverse transcriptase in the presence of magnesium. Biochemistry;42:639650.
  • 40
    Kanaya S., Katsuda-Nakai C., Ikehara M. (1991) Importance of the positive charge cluster in Escherichia coli ribonuclease HI for the effective binding of the substrate. J Biol Chem;266:1162111627.
  • 41
    Mueller G.A., Pari K., DeRose E.F., Kirby T.W., London R.E. (2004) Backbone dynamics of the RNase H domain of HIV-1 reverse transcriptase. Biochemistry;43:93329342.
  • 42
    Rejto P.A., Verkhivker G.M. (1996) Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. Proc Natl Acad Sci U S A;93:89458950.
  • 43
    McCammon J.A. (1998) Theory of biomolecular recognition. Curr Opin Struct Biol;8:245249.
  • 44
    Verkhivker G.M., Bouzida D., Gehlhaar D.K., Rejto P.A., Freer S.T., Rose P.W. (2002) Complexity and simplicity of ligand-macromolecule interactions: the energy landscape perspective. Curr Opin Struct Biol;12:197203.
  • 45
    Termiz N.A., Bahar I. (2002) Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins;49:6170.
  • 46
    Seckler J.M., Howard K.J., Barkley M.D., Wintrode P.L. (2009) Solution structural dynamics of HIV-1 reverse transcriptase heterodimer. Biochemistry;48:76467655.
  • 47
    Seckler J.M., Barkley M.D., Wintrode P.L. (2011) Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding. Biophys J;100:144153.
  • 48
    Arico-Muendel C.C., Patera A., Pochapsky T.C., Kuti M., Wolfson A.J. (1999) Solution structure and dynamics of a serpin reactive site loop using interleukin 1beta as a presentation scaffold. Protein Eng;12:189202.
  • 49
    Ishima R., Torchia D.A., Lynch S.M., Gronenborn A.M., Louis J.M. (2003) Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. J Biol Chem;278:4331143319.
  • 50
    Libonati M., Gotte G. (2004) Oligomerization of bovine ribonuclease A: structural and functional features of its multimers. Biochem J;380:311327.
  • 51
    Sambashivan S., Liu Y., Sawaya M.R., Gingery M., Eisenberg D. (2005) Amyloid-like fibrils of ribonuclease A with three-dimensional domain-swapped and native-like structure. Nature;437:266269.
  • 52
    Baek J.H., Im H., Kang U.B., Seong K.M., Lee C., Kim J., Yu M.H. (2007) Probing the local conformational change of alpha1-antitrypsin. Protein Sci;16:18421850.
  • 53
    Gronenborn A.M. (2009) Protein acrobatics in pairs – dimerization via domain swapping. Curr Opin Struct Biol;19:3949.
  • 54
    Miller K.H., Karr J.R., Marqusee S. (2010) A hinge region cis-proline in ribonuclease A acts as a conformational gatekeeper for C-terminal domain swapping. J Mol Biol;400:567578.
  • 55
    Sonnen A.F., Yu C., Evans E.J., Stuart D.I., Davis S.J., Gilbert R.J. (2010) Domain metastability: a molecular basis for immunoglobulin deposition? J Mol Biol;399:207213.
  • 56
    Rong Y.W., Carl P.L. (1990) On the molecular weight and subunit composition of calf thymus ribonuclease H1. Biochemistry;29:3839.
  • 57
    Lim D., Gregorio G.G., Bingman C., Martinez-Hackert E., Hendrickson W.A., Goff S.P. (2006) Crystal structure of the moloney murine leukemia virus RNase H domain. J Virol;80:83798389.
  • 58
    Kern G., Handel T., Tracy M., Marqusee S. (1998) Characterization of a folding intermediate from HIV-1 ribonuclease H. Protein Sci;7:21642174.